Azilsartan Medoxomil is an orally available angiotensin II type 1 (AT1) receptor antagonist with IC50 value of 2.6 nM.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
靶点 |
|
描述 | Azilsartan Medoxomil, a new angiotensin II Type 1 receptor blockers with IC50 of 0.62 nM. In conscious spontaneously hypertensive rats (SHRs), oral administration of 0.1-1mg/kg azilsartan medoxomil significantly reduced blood pressure at all doses even 24h after dosing[3]. Azilsartan medoxomil, in 40 and 80 mg doses, combined with 5 mg of the calcium channel blocker amlodipine was well tolerated and led to meaningful additional BP(blood pressure) reductions compared with placebo plus amlodipine[4]. Further, in aortic endothelial cells, azilsartan inhibited cell proliferation at concentrations as low as 1 μmol/l. Antiproliferative effects of azilsartan were also observed in cells lacking AT1(angiotensin II type 1) receptors[5]. |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT01715584 | Hypertension | Phase 4 | Recruiting | December 31, 2019 | Canada, Ontario ... 展开 >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD 519 685 8500 ext 58525 Craig.Railton@lhsc.on.ca Principal Investigator: Craig J Railton, MD, PhD Sub-Investigator: Jonathan Fairbairn, BSc Sub-Investigator: George Nicoloau, MD Sub-Investigator: Robert Gros, PhD Sub-Investigator: Jason Franklin, MD Sub-Investigator: John Yoo, MD Sub-Investigator: Kevin Fung, MD Sub-Investigator: Anthony Nichols, MD Sub-Investigator: Danielle McNeil, MD 收起 << |
NCT02235909 | Hypertension | Phase 3 | Recruiting | August 2020 | - |
NCT00762736 | Diabetes Mellitus | Phase 2 | Completed | - | - |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.76mL 0.35mL 0.18mL |
8.79mL 1.76mL 0.88mL |
17.59mL 3.52mL 1.76mL |
CAS号 | 863031-21-4 |
分子式 | C30H24N4O8 |
分子量 | 568.53 |
SMILES Code | O=C(C1=C2N(CC3=CC=C(C4=CC=CC=C4C(N5)=NOC5=O)C=C3)C(OCC)=NC2=CC=C1)OCC6=C(C)OC(O6)=O |
MDL No. | MFCD19443688 |
别名 | TAK-491 |
运输 | 蓝冰 |
InChI Key | QJFSABGVXDWMIW-UHFFFAOYSA-N |
Pubchem ID | 135409642 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere, 2-8°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|